Phase II trial of polifeprosan 20 with carmustine implant, Interferon-beta and Temozolomide Combination Chemoradiotherapy for Newly Diagnosed Glioblastomas

Trial Profile

Phase II trial of polifeprosan 20 with carmustine implant, Interferon-beta and Temozolomide Combination Chemoradiotherapy for Newly Diagnosed Glioblastomas

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 May 2016

At a glance

  • Drugs Carmustine polifeprosan 20 wafer (Primary) ; Interferon beta; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top